title: Reply from Daniel C. Andersson, Matthew J. Betzenhauser, Steven Reiken, Alisa Umanskaya, Takayuki Shiomi and Andrew R. Marks.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Andersson
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Betzenhauser
authors.forename: Steven
authors.initials: S
authors.lastname: Reiken
authors.forename: Alisa
authors.initials: A
authors.lastname: Umanskaya
authors.forename: Takayuki
authors.initials: T
authors.lastname: Shiomi
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Marks
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D007545:Isoproterenol / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects*; D018656:Muscle Fibers, Fast-Twitch / Q000187:drug effects*; D053580:Muscle Strength / Q000187:drug effects*; D019837:Ryanodine Receptor Calcium Release Channel / Q000378:metabolism*
chemical_list: D000318:Adrenergic beta-Agonists; D019837:Ryanodine Receptor Calcium Release Channel; D017868:Cyclic AMP-Dependent Protein Kinases; D007545:Isoproterenol